---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-200476"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2022-07-25T23:59:59+00:00"
generated_at: "2026-06-24T09:20:00.231591+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD extends loan maturity to July 27, appoints CRO, explores Chapter 11

## Summary
- Amendment No. 13 extends Financing Agreement maturity to July 27, 2022.
- Company pays Lenders $2.9 million interest payment as part of amendment.
- Jeffrey Varsalone of G2 Capital Advisors appointed as Chief Restructuring Officer.
- Board evaluating all options including refinancing, strategic alternatives, and Chapter 11.
- Company intends to maintain normal operations while evaluating options.

## SEC filing metadata
- accession: 0001193125-22-200476
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2022-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000119312522200476/0001193125-22-200476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000119312522200476/d387303d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-200476
- JSON: https://secwatch.observer/filing/0001193125-22-200476.json
- Plain text: https://secwatch.observer/filing/0001193125-22-200476.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.